Ansong, Daniel; Asante, Kwaku P; Vekemans, Johan; Owusu, Sandra K; Owusu, Ruth; Brobby, Naana AW; Dosoo, David; Osei-Akoto, Alex; Osei-Kwakye, Kingsley; Asafo-Adjei, Emmanuel; +19 more... Boahen, Kwadwo O; Sylverken, Justice; Adjei, George; Sambian, David; Apanga, Stephen; Kayan, Kingsley; Janssens, Michel H; Lievens, Marc JJ; Olivier, Aurelie C; Jongert, Erik; Dubois, Patrice; Savarese, Barbara M; Cohen, Joe; Antwi, Sampson; Greenwood, Brian M; Evans, Jennifer A; Agbenyega, Tsiri; Moris, Philippe J; Owusu-Agyei, Seth; (2011) T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PloS one, 6 (4). e18891-. ISSN 1932-6203 DOI: https://doi.org/10.1371/journal.pone.0018891
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: The Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being developed for protection of young children against malaria in sub-Saharan Africa. RTS,S formulated with the liposome based adjuvant AS01(E) or the oil-in-water based adjuvant AS02(D) induces P. falciparum circumsporozoite (CSP) antigen-specific antibody and T cell responses which have been associated with protection in the experimental malaria challenge model in adults. METHODS: This study was designed to evaluate the safety and immunogenicity induced over a 19 month period by three vaccination schedules (0,1-, 0,1,2- and 0,1,7-month) of RTS,S/AS01(E) and RTS,S/AS02(D) in children aged 5-17 months in two research centers in Ghana. Control Rabies vaccine using the 0,1,2-month schedule was used in one of two study sites. RESULTS: Whole blood antigen stimulation followed by intra-cellular cytokine staining showed RTS,S/AS01(E) induced CSP specific CD4 T cells producing IL-2, TNF-α, and IFN-γ. Higher T cell responses were induced by a 0,1,7-month immunization schedule as compared with a 0,1- or 0,1,2-month schedule. RTS,S/AS01(E) induced higher CD4 T cell responses as compared to RTS,S/AS02(D) when given on a 0,1,7-month schedule. CONCLUSIONS: These findings support further Phase III evaluation of RTS,S/AS01(E). The role of immune effectors and immunization schedules on vaccine protection are currently under evaluation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00360230.
Item Type | Article |
---|---|
Keywords | FALCIPARUM CIRCUMSPOROZOITE-PROTEIN, RANDOMIZED CONTROLLED-TRIAL, IMMUNE ADULT MEN, DOUBLE-BLIND, LIVER STAGES, B-CELL, SAFETY, IMMUNOGENICITY, EFFICACY, ANTIGEN |
Faculty and Department | Faculty of Infectious and Tropical Diseases > Dept of Disease Control |
Research Centre |
Centre for Maternal, Reproductive and Child Health (MARCH) Malaria Centre Vaccine Centre |
PubMed ID | 21556142 |
ISI | 290019400012 |
Related URLs |